5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice

Salvage chemotherapy for patients with unresectable pancreatic cancer (UR-PC) who have been treated with gemcitabine and nab-paclitaxel (GnP), and 5-fluorouracil (5-FU)/l-leucovorin (LV) plus nanoliposomal irinotecan (nal-IRI), has not been fully established. We retrospectively reviewed data from 17...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamai, Takuo, Ikezawa, Kenji, Kawamoto, Yasuharu, Hirao, Takeru, Higashi, Sena, Daiku, Kazuma, Maeda, Shingo, Abe, Yutaro, Urabe, Makiko, Kai, Yugo, Takada, Ryoji, Nakabori, Tasuku, Uehara, Hiroyuki, Ohkawa, Kazuyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026505/
https://www.ncbi.nlm.nih.gov/pubmed/35448190
http://dx.doi.org/10.3390/curroncol29040216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026505/
https://www.ncbi.nlm.nih.gov/pubmed/35448190
http://dx.doi.org/10.3390/curroncol29040216

Ejemplares similares